Skip to main content

Jefferies Sticks to Their Buy Rating for Inovio Pharmaceuticals (INO)

Tipranks - Tipranks - Thu Aug 14, 2025

Jefferies analyst Roger Song maintained a Buy rating on Inovio Pharmaceuticals today and set a price target of $1.80. The company’s shares opened today at $1.50.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Song covers the Healthcare sector, focusing on stocks such as Replimune Group, United Therapeutics, and Inovio Pharmaceuticals. According to TipRanks, Song has an average return of -19.5% and a 27.62% success rate on recommended stocks.

Inovio Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $6.05, representing a 303.33% upside. In a report released today, Piper Sandler also maintained a Buy rating on the stock with a $5.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

INO market cap is currently $75.93M and has a P/E ratio of -0.47.

Read More on INO:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).